Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMC Effectiveness and Efficacy in Karamoja, Uganda
NCT05323721Phase 4Unknown
- Sponsor
- Malaria Consortium
- Start
- Jun 2022
- Primary completion
- Nov 2022
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sulfadoxine + pyrimethamine + amodiaquine and dihydroartemisinin + piperaquine in malaria, sponsored by Malaria Consortium. Primary endpoint: Malaria incidence at 4 months. Status: unknown.
02
Drugs
sulfadoxine + pyrimethamine + amodiaquinedihydroartemisinin + piperaquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05323721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05323721.